首页> 外国专利> Process for the preparation of ISATX247 mixture enriched with isomer (E), process for the preparation of ISATX247 mixture enriched with isomer (Z), process for stereoselective synthesis of isomer (E) ISATX247, process for stereoselective synthesis of isomer (Z) ISATX247 and process for the preparation a mixture of ISATX247 isomers

Process for the preparation of ISATX247 mixture enriched with isomer (E), process for the preparation of ISATX247 mixture enriched with isomer (Z), process for stereoselective synthesis of isomer (E) ISATX247, process for stereoselective synthesis of isomer (Z) ISATX247 and process for the preparation a mixture of ISATX247 isomers

机译:制备富含异构体的ISATX247混合物的方法(E),制备富含异构体的ISATX247混合物的方法(Z),异构体的立体选择性合成的方法(E)ISATX247,异构体的立体选择性合成的方法(Z)ISATX247和ISATX247异构体混合物的制备方法

摘要

The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISA Tx 247, and derivatives thereof. Mixtures of ISA Tx 247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISA Tx 247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. Stereoselective pathways may utilize a Wittig reaction, or an organometallic reagent comprising inorganic elements such as boron, silicon, titanium, and lithium. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.
机译:本发明涉及结构上类似于环孢菌素A的环孢菌素类似物的异构体混合物。该混合物相对于单个异构体以及天然存在的和其他目前已知的环孢菌素和环孢菌素衍生物具有增强的功效和降低的毒性。本发明的实施方案涉及环孢菌素A类似物的顺式和反式异构体,称为ISA Tx 247,及其衍生物。与天然存在的和目前已知的环孢菌素相比,ISA Tx 247异构体的混合物显示出增强的效能和降低的毒性。 ISA Tx 247异构体以及烷基化,芳基化和氘代衍生物是通过立体选择性途径合成的,其中特定的反应条件决定了立体选择性的程度。立体选择性途径可以利用维蒂希反应或包含诸如硼,硅,钛和锂的无机元素的有机金属试剂。基于混合物的总重量,混合物中异构体的比例可以为(E)-异构体的约10至90重量%至(Z)-异构体的约90至10重量%。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号